Literature DB >> 30425068

Timing of treatment of smoldering myeloma: early treatment.

María-Victoria Mateos1, Verónica González-Calle1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30425068      PMCID： PMC6234377          DOI： 10.1182/bloodadvances.2018021220

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  22 in total

1.  Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.

Authors:  María-Victoria Mateos; Miguel-Teodoro Hernández; Pilar Giraldo; Javier de la Rubia; Felipe de Arriba; Lucía López Corral; Laura Rosiñol; Bruno Paiva; Luis Palomera; Joan Bargay; Albert Oriol; Felipe Prosper; Javier López; José-María Arguiñano; Nuria Quintana; José-Luis García; Joan Bladé; Juan-José Lahuerta; Jesús-F San Miguel
Journal:  Lancet Oncol       Date:  2016-07-09       Impact factor: 41.316

2.  Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study.

Authors:  Rasmus Sørrig; Tobias W Klausen; Morten Salomo; Annette J Vangsted; Brian Østergaard; Henrik Gregersen; Ulf Christian Frølund; Niels F Andersen; Carsten Helleberg; Kristian T Andersen; Robert S Pedersen; Per Pedersen; Niels Abildgaard; Peter Gimsing
Journal:  Eur J Haematol       Date:  2016-02-05       Impact factor: 2.997

3.  Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

Authors:  María-Victoria Mateos; Miguel-Teodoro Hernández; Pilar Giraldo; Javier de la Rubia; Felipe de Arriba; Lucía López Corral; Laura Rosiñol; Bruno Paiva; Luis Palomera; Joan Bargay; Albert Oriol; Felipe Prosper; Javier López; Eduardo Olavarría; Nuria Quintana; José-Luis García; Joan Bladé; Juan-José Lahuerta; Jesús-F San Miguel
Journal:  N Engl J Med       Date:  2013-08-01       Impact factor: 91.245

4.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

Authors:  Ernesto Pérez-Persona; María-Belén Vidriales; Gema Mateo; Ramón García-Sanz; Maria-Victoria Mateos; Alfonso García de Coca; Josefina Galende; Guillermo Martín-Nuñez; José M Alonso; Natalia de Las Heras; José M Hernández; Alejandro Martín; Consuelo López-Berges; Alberto Orfao; Jesús F San Miguel
Journal:  Blood       Date:  2007-06-18       Impact factor: 22.113

5.  Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect.

Authors:  Alejandro Martín; Ramón García-Sanz; José Hernández; Joan Bladé; Begoña Suquía; Javier Fernández-Calvo; Marcos González; Gema Mateo; Alberto Orfao; Jesus F San Miguel
Journal:  Br J Haematol       Date:  2002-07       Impact factor: 6.998

6.  A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.

Authors:  Pellegrino Musto; Maria Teresa Petrucci; Sara Bringhen; Tommasina Guglielmelli; Tommaso Caravita; Velia Bongarzoni; Alessandro Andriani; Giovanni D'Arena; Enrico Balleari; Giuseppe Pietrantuono; Mario Boccadoro; Antonio Palumbo
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

7.  Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden.

Authors:  M Hjorth; L Hellquist; E Holmberg; B Magnusson; S Rödjer; J Westin
Journal:  Eur J Haematol       Date:  1993-02       Impact factor: 2.997

8.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.

Authors:  Robert A Kyle; Ellen D Remstein; Terry M Therneau; Angela Dispenzieri; Paul J Kurtin; Janice M Hodnefield; Dirk R Larson; Matthew F Plevak; Diane F Jelinek; Rafael Fonseca; Lee Joseph Melton; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

9.  Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.

Authors:  Kai Neben; Anna Jauch; Thomas Hielscher; Jens Hillengass; Nicola Lehners; Anja Seckinger; Martin Granzow; Marc S Raab; Anthony D Ho; Hartmut Goldschmidt; Dirk Hose
Journal:  J Clin Oncol       Date:  2013-10-21       Impact factor: 44.544

10.  Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma.

Authors:  P Ravi; S Kumar; J T Larsen; W Gonsalves; F Buadi; M Q Lacy; R Go; A Dispenzieri; P Kapoor; J A Lust; D Dingli; Y Lin; S J Russell; N Leung; M A Gertz; R A Kyle; P L Bergsagel; S V Rajkumar
Journal:  Blood Cancer J       Date:  2016-07-29       Impact factor: 11.037
View more
  4 in total

Review 1.  Progress in the Management of Smoldering Multiple Myeloma.

Authors:  Timothy M Schmidt; Natalie S Callander
Journal:  Curr Hematol Malig Rep       Date:  2021-05-13       Impact factor: 3.952

Review 2.  B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review.

Authors:  Ryan B Sinit; Dick G Hwang; Prakash Vishnu; Jess F Peterson; David M Aboulafia
Journal:  BMC Cancer       Date:  2019-11-27       Impact factor: 4.430

Review 3.  The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma.

Authors:  E Zamagni; P Tacchetti; P Deias; F Patriarca
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-10

Review 4.  Actors on the Scene: Immune Cells in the Myeloma Niche.

Authors:  Patrizia Leone; Antonio Giovanni Solimando; Eleonora Malerba; Rossella Fasano; Alessio Buonavoglia; Fabrizio Pappagallo; Valli De Re; Antonella Argentiero; Nicola Silvestris; Angelo Vacca; Vito Racanelli
Journal:  Front Oncol       Date:  2020-10-29       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.